Abbott Laboratories reported Q3 sales of $10.64 billion, driven by 8.2% organic growth in medical devices. Adjusted EPS for 2024 projected at $4.64-$4.70, with expectations of double-digit growth ...

Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The ...

Abbott Laboratories (NYSE:ABT) reported better-than-expected third-quarter results on Wednesday. The company posted sales of ...

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...

Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the ...

Abbott Laboratories raised its 2024 earnings guidance after strong Q3 results, driven by growth in Pharma and MedTech ...

Abbott has raised the midpoint of its full-year income guidance as the group was bolstered by solid sales of medical devices ...

On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street ...

Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B ... beating the analyst estimates of $1.20. Also Read: ...